Investornewsbreaks Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio With Approval For PTSD Treatment SPC-15

(MENAFN- Investor Brand Network) Silo Pharma (NASDAQ: SILO) received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent supporting its lead asset, SPC-15, an intranasal treatment for PTSD. The patent, expected to be formally issued within 90 days, builds on Silo's existing intellectual property and expands protection for SPC-15, a serotonin 5-HT4 receptor agonist designed for stress-induced disorders like PTSD and anxiety. Licensed exclusively from Columbia University, SPC-15 is in preclinical studies and may benefit from the FDA's expedited 505(b)(2) regulatory pathway.

To view the full press release, visit

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system (“CNS”) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug-delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo's two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo's research and development programs are conducted through collaborations with universities and independent laboratories. For more information about the company, visit

.

NOTE TO INVESTORS:
The latest news and updates relating to SILO are available in the company's newsroom at

About InvestorWire

InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by
IBN

MENAFN08012025000224011066ID1109070544